Ashley Trood
Physician Assistant · Wichita, KSNPI 1285379164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,608, 3.7 times the $699 reported in 2022. Among physician assistant clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$873
- Dexcom, Inc.$728
- Amgen$711
- Bayer$570
- Recordati_rare_diseases_inc.$397
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,393100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 62 | $1,317 |
| Novo Nordisk | 55 | $873 |
| Dexcom, Inc. | 51 | $728 |
| Amgen | 34 | $711 |
| Bayer | 40 | $570 |
| Recordati_rare_diseases_inc. | 18 | $397 |
| Corcept Therapeutics | 28 | $348 |
| Insulet Corporation | 46 | $330 |
| Xeris Pharmaceuticals, Inc. | 19 | $274 |
| Boehringer Ingelheim | 15 | $263 |
| Sanofi-aventis U.S. LLC | 8 | $172 |
| Neurocrine Biosciences, Inc. | 14 | $162 |
| AstraZeneca | 8 | $139 |
| AbbVie | 9 | $135 |
| Novartis | 6 | $130 |
| Radius Health, Inc. | 4 | $116 |
| Currax Pharmaceuticals LLC | 5 | $90 |
| Nevro Corp. | 2 | $81 |
| BETA Bionics, Inc. | 6 | $70 |
| Almatica Pharma LLC | 4 | $68 |
| Sequel Med Tech, LLC | 3 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Globus Medical | 1 | $50 |
| EUSA Pharma (US) LLC | 3 | $48 |
| Medtronic | 2 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Averitas Pharma Inc. | 1 | $29 |
| Recor Medical Inc | 1 | $22 |
| Merck | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Embecta Corp. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
How this compares
$7,418 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 311 | $330,514 |
| JardianceEmpagliflozin | 196 | $204,680 |
| TrulicityDulaglutide | 121 | $115,248 |
| MounjaroTirzepatide | 87 | $92,442 |
| FarxigaDapagliflozin Propanediol | 27 | $37,250 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $36,939 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $35,731 |
| JanuviaSitagliptin Phosphate | 35 | $30,327 |
| ProliaDenosumab | 15 | $25,688 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $23,588 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $16,252 |
| Novolog FlexpenInsulin Aspart | 61 | $14,064 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $12,598 |
| Humalog Kwikpen U-100Insulin Lispro | 40 | $9,753 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 31 | $9,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $873 | $330,514311 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,317 | $212,335224 claims |
| Boehringer IngelheimJardiance | $263 | $204,680196 claims |
| AstraZenecaFarxiga | $139 | $37,25027 claims |
| MerckJanuvia | $18 | $30,32735 claims |
| AmgenProlia | $711 | $25,68815 claims |
| AbbVieSynthroid | $135 | $7,27278 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $3,141421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Wichita
- Sierra FergusonWichita$25K
- Ashton YoungersWichita$14K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Jenny MartensWichita$13K
- Shanna SudermanWichita$13K
- Megan HolickWichita$12K
- Colleen YoungWichita$11K
- Kathleen Dang-PhamWichita$11K
- Trinh HoangWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.